Payers are prepared to implement coverage restrictions for upcoming cholesterol-reducing drugs in the PCSK9 inhibitor class to balance the cost of the agents, which would include controls to ensure the drugs are prescribed only for patients who have hard-to-treat forms of hypercholesterolemia or have been proven not to respond to less costly treatments.
That was a lesson learned from the launch of Gilead Sciences Inc.’s high-priced hepatitis C treatment Sovaldi (sofosbuvir). Many...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?